GT200200051A - Conjugados de pregabalina-lactosa - Google Patents
Conjugados de pregabalina-lactosaInfo
- Publication number
- GT200200051A GT200200051A GT200200051A GT200200051A GT200200051A GT 200200051 A GT200200051 A GT 200200051A GT 200200051 A GT200200051 A GT 200200051A GT 200200051 A GT200200051 A GT 200200051A GT 200200051 A GT200200051 A GT 200200051A
- Authority
- GT
- Guatemala
- Prior art keywords
- pregabaline
- conjugates
- lactose conjugates
- lactose
- pregabalinalactose
- Prior art date
Links
- 239000008101 lactose Substances 0.000 title 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 208000008238 Muscle Spasticity Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000002920 convulsive effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000018198 spasticity Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A CONJUGADOS DE PREGABALINALACTOSA DE FORMULAS GENERALES QUE SE MUESTRAN EN EL EXPEDIENTE Y QUE SON UTILES EN ESTADOS CONVULSIVOS, TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL COMO ISQUEMIA CEREBRAL, PARKINSON, ESPASTICIDAD Y ESTADOS DE ANSIEDAD, DEPRESION, PSICOSIS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28017601P | 2001-03-30 | 2001-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT200200051A true GT200200051A (es) | 2002-11-15 |
Family
ID=23072002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT200200051A GT200200051A (es) | 2001-03-30 | 2002-03-19 | Conjugados de pregabalina-lactosa |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US7022678B2 (es) |
| EP (1) | EP1377318A2 (es) |
| JP (1) | JP2004524357A (es) |
| KR (1) | KR20040008146A (es) |
| CN (1) | CN1511043A (es) |
| AP (1) | AP2003002873A0 (es) |
| AR (1) | AR033024A1 (es) |
| BG (1) | BG108193A (es) |
| BR (1) | BR0208439A (es) |
| CA (1) | CA2440468C (es) |
| CZ (1) | CZ20032547A3 (es) |
| DO (1) | DOP2002000356A (es) |
| EA (1) | EA200300954A1 (es) |
| EC (1) | ECSP034740A (es) |
| EE (1) | EE200300480A (es) |
| GT (1) | GT200200051A (es) |
| HU (1) | HUP0303956A2 (es) |
| IL (1) | IL157879A0 (es) |
| IS (1) | IS6912A (es) |
| MA (1) | MA27004A1 (es) |
| MX (1) | MXPA03007437A (es) |
| NO (1) | NO20034348D0 (es) |
| OA (1) | OA12456A (es) |
| PA (1) | PA8542101A1 (es) |
| PE (1) | PE20021016A1 (es) |
| PL (1) | PL369179A1 (es) |
| SK (1) | SK11832003A3 (es) |
| SV (1) | SV2003000928A (es) |
| TN (1) | TNSN02038A1 (es) |
| UY (1) | UY27233A1 (es) |
| WO (1) | WO2002078747A2 (es) |
| ZA (1) | ZA200306608B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1094757C (zh) | 1996-07-24 | 2002-11-27 | 沃尼尔·朗伯公司 | 用于治疗疼痛的异丁基γ－氨基丁酸及其衍生物 |
| WO2007035789A1 (en) * | 2005-09-19 | 2007-03-29 | Teva Pharmaceutical Industries Ltd. | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the new synthesis of (s)-pregabalin |
| DE102007019071A1 (de) | 2007-04-23 | 2008-10-30 | Ratiopharm Gmbh | Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin |
| EP2116618A1 (en) | 2008-05-09 | 2009-11-11 | Agency for Science, Technology And Research | Diagnosis and treatment of Kawasaki disease |
| WO2009158343A1 (en) * | 2008-06-23 | 2009-12-30 | Teva Pharmaceutical Industries, Ltd. | Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester |
| WO2010115612A2 (en) | 2009-04-10 | 2010-10-14 | Synthon B.V. | Pregabalin compositions |
| WO2010150221A1 (en) | 2009-06-25 | 2010-12-29 | Wockhardt Research Centre | Taste masked pharmaceutical compositions of pregabalin |
| HU230031B1 (hu) * | 2010-03-01 | 2015-05-28 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény |
| CN103494796B (zh) * | 2013-09-30 | 2016-01-20 | 浙江华义医药有限公司 | 普瑞巴林稳定的药物组合物及其制备方法 |
| CN104370986B (zh) * | 2014-10-28 | 2017-07-04 | 河南中烟工业有限责任公司 | 糖衍生物烟用增香保润剂Mal‑Pro、制备方法及其应用 |
| CN104311608B (zh) * | 2014-10-28 | 2016-10-05 | 河南中烟工业有限责任公司 | 亲水型烟草增香保润剂Mal-Hyp、制备方法及其应用 |
| CN105434395B (zh) * | 2015-12-31 | 2018-12-11 | 常州市阳光药业有限公司 | 普瑞巴林胶囊及其制备方法 |
| CN105520918B (zh) * | 2015-12-31 | 2018-12-11 | 常州市阳光药业有限公司 | 普瑞巴林胶囊 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197819B1 (en) | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
| FR2781793B1 (fr) * | 1998-08-03 | 2001-07-20 | Prographarm Lab | Procede de fabrication de granules de gabapentine enrobes |
| CA2344407C (en) * | 1998-10-16 | 2007-01-09 | Warner-Lambert Company | Method for the treatment of mania and bipolar disorder |
| BR0115783A (pt) * | 2000-11-30 | 2003-09-16 | Pfizer Prod Inc | Combinação de agonistas de gaba e inibidores de sorbitol desidrogenase |
-
2002
- 2002-01-28 US US10/058,903 patent/US7022678B2/en not_active Expired - Fee Related
- 2002-02-25 KR KR10-2003-7012714A patent/KR20040008146A/ko not_active Ceased
- 2002-02-25 EP EP02702614A patent/EP1377318A2/en not_active Withdrawn
- 2002-02-25 BR BR0208439-2A patent/BR0208439A/pt not_active IP Right Cessation
- 2002-02-25 MX MXPA03007437A patent/MXPA03007437A/es active IP Right Grant
- 2002-02-25 SK SK1183-2003A patent/SK11832003A3/sk not_active Application Discontinuation
- 2002-02-25 EE EEP200300480A patent/EE200300480A/xx unknown
- 2002-02-25 WO PCT/IB2002/000647 patent/WO2002078747A2/en not_active Ceased
- 2002-02-25 EA EA200300954A patent/EA200300954A1/ru unknown
- 2002-02-25 CN CNA028067509A patent/CN1511043A/zh active Pending
- 2002-02-25 OA OA1200300232A patent/OA12456A/en unknown
- 2002-02-25 PL PL02369179A patent/PL369179A1/xx not_active Application Discontinuation
- 2002-02-25 HU HU0303956A patent/HUP0303956A2/hu unknown
- 2002-02-25 AP APAP/P/2003/002873A patent/AP2003002873A0/en unknown
- 2002-02-25 CZ CZ20032547A patent/CZ20032547A3/cs unknown
- 2002-02-25 IL IL15787902A patent/IL157879A0/xx unknown
- 2002-02-25 JP JP2002577011A patent/JP2004524357A/ja active Pending
- 2002-02-25 CA CA002440468A patent/CA2440468C/en not_active Expired - Fee Related
- 2002-03-07 DO DO2002000356A patent/DOP2002000356A/es unknown
- 2002-03-19 GT GT200200051A patent/GT200200051A/es unknown
- 2002-03-22 SV SV2002000928A patent/SV2003000928A/es not_active Application Discontinuation
- 2002-03-27 PA PA20028542101A patent/PA8542101A1/es unknown
- 2002-03-27 AR ARP020101140A patent/AR033024A1/es unknown
- 2002-03-27 PE PE2002000252A patent/PE20021016A1/es not_active Application Discontinuation
- 2002-03-27 UY UY27233A patent/UY27233A1/es not_active Application Discontinuation
- 2002-03-29 TN TNTNSN02038A patent/TNSN02038A1/fr unknown
-
2003
- 2003-08-14 IS IS6912A patent/IS6912A/is unknown
- 2003-08-21 EC EC2003004740A patent/ECSP034740A/es unknown
- 2003-08-25 ZA ZA200306608A patent/ZA200306608B/en unknown
- 2003-09-17 MA MA27315A patent/MA27004A1/fr unknown
- 2003-09-24 BG BG108193A patent/BG108193A/xx unknown
- 2003-09-29 NO NO20034348A patent/NO20034348D0/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT200200051A (es) | Conjugados de pregabalina-lactosa | |
| GT200300150A (es) | Inhibidores de quinasas | |
| WO2004058704A8 (en) | Quinazolinones as potassium channel modulators | |
| GT200200269A (es) | Derivados de 7-amino-benzotiazol | |
| GT200400032A (es) | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transformante (tgf) | |
| GT200300219A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos | |
| GT200400161A (es) | Piridinonas sustituidas | |
| GT200300101A (es) | Pirazolopiridinas substituidas con carbamato | |
| GT200600128A (es) | Derivados de ciclopentapiridina y tetrahidroquinolina | |
| GT200300177A (es) | Terapia de combinacion para enfermedades hiperproliferativas | |
| HN2000000051A (es) | Derivados heterociclicos utiles como agentes anticancerosos | |
| GT200300057A (es) | Derivados de aminoindazoles, proceso de preparacion e intermediarios de ese proceso a titulos de medicamentos y composiciones farmaceuticas que los concentran | |
| GT200200122A (es) | Imidazotriazinas | |
| GT200300093A (es) | Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida | |
| PA8468501A1 (es) | Compuestos heterociclicos como inhibidores de enzimas rotamasas | |
| GT200300226A (es) | 4-piperazinilbencenosulfonilindoles y usos de los mismos | |
| WO2005025293A3 (en) | Fused ring heterocycles as potassium channel modulators | |
| GT200200072A (es) | Derivados de dihidro-benzo (b) (1,4)-diazepin-2-ona | |
| HN2001000013A (es) | PIRIDO [2,3 - d] PIRIMIDIN - 2, 7 - DIAMINAS INHIBIDORES DE CINASAS | |
| GT200200216A (es) | Derivados del 3-azabiciclo [3.1.0] hexano | |
| GT200200280A (es) | Lactamas como antagonistas de taquiquininas | |
| GT200500187A (es) | Moduladores de andrògenos | |
| GT200300241A (es) | Benzoxazinonas sustituidas y usos de las mismas | |
| GT200300095A (es) | Derivados de isoquinolina | |
| GT200200074A (es) | Aminoacidos biciclicos o triciclicos condensados |